about
Models for thrombin generation and risk of diseaseAnticoagulants and the propagation phase of thrombin generationKinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.Defining the boundaries of normal thrombin generation: investigations into hemostasisIs there value in kinetic modeling of thrombin generation? Yes.Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization.The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation.Rivaroxaban delivery and reversal at a venous flow rateApixaban in patients with Atrial Fibrillation: A Systematic ReviewLaboratory assessment of new anticoagulants.Modeling thrombin generation: plasma composition based approach.A new direction for anticoagulants: inhibiting fibrin assembly with PEGylated fibrin knob mimics.The Best Anticoagulation Strategy for Cirrhotic Patients who Underwent Splenectomy: A Network Meta-Analysis.Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics.A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.
P2860
Q27013171-10E0047C-44A8-4683-815B-2C8D1774C577Q28742536-15D6A416-5876-42DC-B484-EBB789C28E20Q34026641-FC2D12CA-38E7-4C09-8047-8D2F56429975Q34128442-6AC612A9-E1FB-4FB0-B285-5C980D5F3C53Q34154574-DEFD2F99-B67F-4190-9985-3F5A323BB324Q36008892-F6C05197-28C8-4FEC-83B6-AC081AD2602FQ36093372-82403DF4-F715-40B8-938C-400AC1026469Q36229803-ACB69C92-EE67-4E75-B4C8-891DFBCCE4BCQ36775716-69BE55A1-4113-46BC-8E1B-9E2BFA2B103FQ37495983-A7BBE872-D5A9-417D-AC05-D29452C8FCBCQ37834646-AE4089BF-65D8-4C5F-8DDF-B2EB0FCD960EQ38161459-4A62A1B0-4D42-463A-B3CA-2F8946050D6CQ38341966-354C2F14-DF8C-4502-8D7D-6B0AB4110CC1Q38693795-5A217773-05C1-4F02-90A1-BB3E7C884963Q38990889-C7ABF422-E5D1-413A-8B57-2551AC647508Q40090376-528FAEE4-2EDA-41AD-AB8C-8AD40D6B8DE2Q41823356-0984AD94-E2D2-4913-8D7D-376676B0CAB1Q46175382-B12951DA-A649-42A8-A97A-6A607697CBF4
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anticoagulation by factor Xa inhibitors.
@ast
Anticoagulation by factor Xa inhibitors.
@en
Anticoagulation by factor Xa inhibitors.
@nl
type
label
Anticoagulation by factor Xa inhibitors.
@ast
Anticoagulation by factor Xa inhibitors.
@en
Anticoagulation by factor Xa inhibitors.
@nl
prefLabel
Anticoagulation by factor Xa inhibitors.
@ast
Anticoagulation by factor Xa inhibitors.
@en
Anticoagulation by factor Xa inhibitors.
@nl
P2093
P2860
P1476
Anticoagulation by factor Xa inhibitors.
@en
P2093
K E Brummel-Ziedins
P2860
P304
P356
10.1111/J.1538-7836.2010.03917.X
P577
2010-05-21T00:00:00Z